Choice of P2Y12 Inhibitors After Acute Coronary Syndrome

Am J Cardiol. 2024 Jan 15:211:377. doi: 10.1016/j.amjcard.2023.10.084. Epub 2023 Nov 7.

Authors

Giuseppe Andò¹, Felice Gragnano², Francesco Pelliccia³, Paolo Calabrò²

Affiliations

¹ Department of Clinical and Experimental Medicine, University of Messina, AOU Policlinico "G. Martino", Messina, Italy.
² Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli" and Division of Clinical Cardiology, AORN "Sant'Anna e San Sebastiano", Caserta, Italy.
³ Department of Cardiovascular Sciences, University of Rome "La Sapienza", Rome, Italy.

PMID: 37944777
DOI: 10.1016/j.amjcard.2023.10.084

No abstract available

Publication types

Letter

MeSH terms

Acute Coronary Syndrome* / drug therapy
Clopidogrel / therapeutic use
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / therapeutic use
Prasugrel Hydrochloride
Purinergic P2Y Receptor Antagonists / therapeutic use
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Purinergic P2Y Receptor Antagonists
Prasugrel Hydrochloride